Has Oren Friedman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $277,742 in general payments to Oren Friedman, MD across 408 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Oren Friedman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Oren Friedman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Oren Friedman, MD

Pulmonary Disease · West Hollywood, CANPI 1649435629

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 66.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $119,586 and has fallen 54.2% since, to $54,722 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$277,742in general payments, 2019–2025

Across 408 payments — averaging $680.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Inari Medical, Inc.$184K
Stryker$54K
E.r. Squibb & Sons, L.L.C.$21K
Pfizer$12K
Ambu Inc.$2K
Boston Scientific$1K
plus $4K from 16 others

$60,873in research payments, 2019–2025

Across 24 payments — averaging $2536.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$61K

What the payments were for

Consulting fees$85,95031%
Speaking & faculty fees$140,46051%
Travel & lodging$33,09412%
Food & beverage$18,2387%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Inari Medical, Inc.	251	$184,346
Stryker	45	$53,679
E.r. Squibb & Sons, L.L.C.	37	$20,871
Pfizer	29	$11,965
Ambu Inc.	1	$2,000
Boston Scientific	11	$1,290
Johnson & Johnson	9	$579
Angiodynamics, Inc.	2	$424
Walk Vascular, LLC	2	$400
Imperative Care, Inc	2	$323
Penumbra, Inc.	2	$278
Mallinckrodt Hospital Products Inc.	2	$277
La Jolla Pharmaceutical Company	3	$275
Inquis Medical, Inc.	3	$249
Abiomed	1	$143
Vapotherm Inc	2	$131
Intuitive Surgical	1	$130
United Therapeutics Corporation	1	$122
Truvic Medical, Inc.	1	$119
Actelion Pharmaceuticals US, Inc.	1	$83
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$43
Portola Pharmaceuticals, LLC	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,742 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Medicare billing

Part B allowed, 2024

$125,991

Medicare patients

228

Services billed

715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in West Hollywood

Paul NobleWest Hollywood$306K
Tanzira ZamanWest Hollywood$105K
Samuel LouieSacramento$2.8M
Shyamsunder SubramanianTracy$1.5M
Toby MaherLos Angeles$1.3M
Rajkumar DasguptaPasadena$930K
Hoang leFountain Valley$814K
Kevin FussellEncinitas$788K
Revati ShreeniwasStanford$726K
David PhamWestminster$571K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →